Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole fMRI study in schizophrenia with impulsivity
NCT02194933Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Feb 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Feb 2015; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02194933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194933.